New York, NY Clinical Trials Report — June 2026

For New Yorkers considering participation in clinical research, June 2026 brings a mix of urgent opportunities and exciting new avenues for contributing to medical science. Across New York, NY, a significant number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals.

A total of 208 clinical trials are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 54 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various cancers and other conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (7 trials)
• Prostate cancer (6 trials)
• Ovarian cancer (5 trials)
• Colorectal cancer (4 trials)
• Metastatic malignant solid neoplasm (3 trials)
• NSCLC (3 trials)
• Non-small cell lung cancer (3 trials)
• Melanoma (3 trials)
• Acute myeloid leukemia (3 trials)
• Head and neck cancer (3 trials)

New Research Opportunities Emerge

This month, New York City saw the opening of 62 new clinical trials, an increase from the 58 trials that launched in May 2026. This brings the total number of actively recruiting clinical trials in New York, NY, to 3,141 across 1,295 research facilities, underscoring the city's robust research landscape.

June brings several high-profile new trials to New York, NY, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Kallyope Inc. is initiating a notable Phase 3 study, NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized, multicenter trial aims for 1,800 participants to evaluate the efficacy, safety, and tolerability of elismetrep compared with placebo in the acute treatment of migraine.
• NYU Langone Health is sponsoring NCT07656584, "Implementation of Communication Disability Collection and Accommodations in Primary Care Settings," a multi-methods-multi-site study involving 126,870 participants. This research aims to adapt and evaluate strategies to help primary care clinics document patients' communication disability and accommodation needs in electronic health records.
• Also from NYU Langone Health, NCT07665060, "HIV Antibody Increases Following Viral Rebound in People Receiving Antiretroviral Therapy," seeks 6,100 participants. The purpose of this study is to establish proof-of-concept for whether rapid tests can detect viral rebounds retrospectively among people living with HIV receiving ART.
• Another study sponsored by NYU Langone Health is NCT07631858, "Perspectives About Online Information," with 3,200 participants. This research aims to understand the perspectives of U.S. adults on online information about prostate cancer, with participants viewing different online content and completing a survey.
• Truway Health, Inc. is sponsoring NCT07622589, "NeuroFinance Human Stress Trial During Financial and Informational Volatility." This decentralized observational study aims for 2,500 participants to evaluate how financial market volatility, economic uncertainty, and information-driven stress environments affect human physiologic and behavioral health.
• Convergent Genomics, Inc. is leading NCT07673016, "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer." This prospective, multicenter observational study will collect urine and tumor biospecimens and associated clinical data from 2,500 patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.

New trials this month are exploring a range of conditions, with the most frequent being prostate cancer (4 trials), anxiety (3 trials), bladder cancer (2 trials), myopia (2 trials), HIV (2 trials), and nephrolithiasis (2 trials). Drug trials account for the largest share of new studies, with 22 new drug trials, followed by 15 device trials and 9 behavioral studies.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 7 of the 62 new trials launched this month are actively seeking healthy volunteers. Across New York City, a total of 370 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

New York City's Leading Research Facilities

New York City is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Memorial Sloan Kettering Cancer Center (470 trials)
• NYU Langone Health (252 trials)
• Icahn School of Medicine at Mount Sinai (226 trials)
• Columbia University Irving Medical Center (165 trials)
• Memorial Sloan Kettering Cancer Center (All Protocol Activities) (144 trials)
• Columbia University Medical Center (119 trials)
• Mount Sinai Hospital (117 trials)
• Weill Cornell Medicine (112 trials)
• Columbia University (99 trials)
• Research Site (77 trials)
• Laura and Isaac Perlmutter Cancer Center at NYU Langone (62 trials)
• NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center (61 trials)

These institutions offer a broad spectrum of research, from oncology at Memorial Sloan Kettering and NYU Langone's Perlmutter Cancer Center, to diverse medical fields at NYU Langone Health, Icahn School of Medicine at Mount Sinai, and Columbia University's medical centers.

Broadening Your Search: Nearby Options

While New York City offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within New York State. Cities with active trials include Commack (12 trials), The Bronx (10 trials), Harrison (9 trials), Rochester (9 trials), Uniondale (6 trials), Albany (5 trials), Brooklyn (5 trials), and Manhasset (4 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 62 new trials launched this month, 57 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 7 new trials include children, 2 are female-only, and 4 are male-only. Academic institutions continue to play a vital role in New York City's research ecosystem, with Memorial Sloan Kettering Cancer Center (10 trials), Icahn School of Medicine at Mount Sinai (7 trials), and NYU Langone Health (6 trials) sponsoring the most new studies. Industry sponsors like Kallyope Inc. (2 trials), Candel Therapeutics, Inc. (1 trial), and AusperBio Therapeutics Inc. (1 trial) are also driving significant research efforts.

As we move through June, New York City's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.